| Quarterly Financials | Mar 2019 | Jun 2019 | Sept 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sept 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 |
Revenue  | 251 | 217 | 282 | 190 | 211 | 254 | 247 | 296 | 281 | 293 | 324 | 456 | 381 | 350 | 289 | 367 | 381 | 358 | 251 | 234 | 270 | 508 | 620 | 323 | 853 | 564 | 571 |
| Expenses | 129 | 95 | 147 | 99 | 108 | 126 | 140 | 138 | 166 | 149 | 179 | 206 | 207 | 188 | 179 | 207 | 198 | 181 | 133 | 154 | 180 | 363 | 398 | 189 | 627 | 445 | 435 |
| EBITDA | 122 | 122 | 135 | 91 | 103 | 128 | 107 | 158 | 116 | 144 | 144 | 251 | 174 | 162 | 111 | 160 | 183 | 178 | 118 | 80 | 90 | 145 | 222 | 133 | 226 | 118 | 137 |
| Operating Profit % | 49 % | 52 % | 46 % | 45 % | 41 % | 47 % | 41 % | 50 % | 36 % | 43 % | 40 % | 48 % | 43 % | 45 % | 36 % | 41 % | 47 % | 48 % | 42 % | 30 % | 29 % | 26 % | 34 % | 38 % | 25 % | 19 % | 22 % |
| Depreciation | 6 | 6 | 6 | 6 | 7 | 7 | 8 | 9 | 8 | 9 | 9 | 11 | 10 | 12 | 12 | 12 | 12 | 13 | 12 | 13 | 17 | 31 | 38 | 20 | 54 | 45 | 44 |
| Interest | 2 | 4 | 4 | 8 | 7 | 3 | 3 | 2 | 2 | 2 | 1 | 1 | 2 | 2 | 0 | 1 | 5 | 1 | 1 | 2 | 2 | 10 | 10 | 3 | 10 | 10 | 9 |
| Profit Before Tax | 115 | 113 | 125 | 78 | 89 | 118 | 97 | 148 | 106 | 133 | 134 | 240 | 161 | 149 | 99 | 146 | 166 | 164 | 105 | 66 | 71 | 103 | 174 | 110 | 161 | 63 | 84 |
| Tax | 40 | 21 | 32 | 20 | 15 | 26 | 23 | 34 | 22 | 28 | 37 | 79 | 70 | 41 | 26 | 38 | 42 | 43 | 26 | 19 | 18 | 28 | 36 | 26 | 44 | 16 | 17 |
| Net Profit | 75 | 92 | 93 | 58 | 74 | 92 | 74 | 114 | 83 | 105 | 97 | 160 | 92 | 108 | 72 | 108 | 124 | 121 | 80 | 47 | 53 | 75 | 138 | 83 | 117 | 46 | 66 |
| EPS in ₹ | 5.88 | 7.22 | 3.65 | 4.55 | 5.83 | 3.60 | 2.91 | 4.46 | 3.27 | 4.13 | 3.81 | 6.29 | 3.60 | 4.22 | 2.83 | 4.23 | 4.87 | 4.74 | 3.13 | 1.84 | 2.10 | 1.98 | 3.63 | 3.26 | 3.16 | 1.28 | 1.94 |
Cohance Lifesciences
Cohance Lifesciences
615.50
-13.60
(-2.16%)
Q1 Quarterly Results are out. Check out the updated financials2 days ago
View
Key Fundamentals
Market Cap
23,547.00 Cr
EPS
10.52
PE Ratio
75.16
Dividend Yield
0.00 %
Industry
Healthcare 52 Week High
1,360.00
52 Week Low
621.20
PB Ratio
6.22
Debt to Equity
0.09
Sector
Pharmaceuticals Analyst Rating and Forecast
- By Refinitiv from8 analysts
Actual
Company News
View All News
Cohance Lifesciences Extends Decline to 27% Over 11 Sessions Following Weak Quarterly Results
2 days ago
2 days agoCohance Lifesciences shares fell 10% in their 11th consecutive session of losses, bringing total decline to 27% over this period. Trading volumes surged to 19 lakh shares, significantly above the 20-day average of 2.5 lakh shares. The company's quarterly results showed net profit dropping 52% to ₹66.4 crore while revenue declined 8% to ₹555 crore. EBITDA fell 41% to ₹121.2 crore with margins contracting to 21.8% from 34% previously. The company attributed revenue decline to deferred shipments at CDMO and FDF sites, de-stocking of key molecules, and delayed project starts at NJ Bio. Despite near-term challenges including pharma destocking and project delays, Cohance maintains its target of achieving $1 billion revenue by 2030 with mid-30s EBITDA margins. The company expects improved performance in the second half of FY26 driven by deferred shipments and new commercial project wins.
Cohance Lifesciences Limited reported quarterly results with revenue declining 8% year-on-year to ₹5,556 million, primarily due to deferred shipments at CDMO and FDF sites and key molecule destocking. However, half-year revenue grew 1.2% to ₹11,049 million. Gross margins improved significantly to 73.8% for H1FY26 compared to 70% in the same period last year, driven by business mix and efficiency improvements. Adjusted EBITDA margins were 23.8% for the half-year period. The company secured US FDA approval for a Phase III drug from an innovator partner and executed a large Phase II order for a global innovator. Challenges included pharma destocking in key molecules, delayed biotech project shipments pushed by 2-3 quarters due to extended CMC timelines, and temporary Nacharam plant shutdown. The company maintains its target of achieving USD 1 billion revenue by 2030 with mid-30s EBITDA margins.
Cohance Lifesciences Outlines Growth Strategy Through CRAMS and Specialty APIs3 days ago
Cohance Lifesciences has outlined its growth strategy focusing on CRAMS (Contract Research and Manufacturing Services), specialty APIs, and formulations. The company is expanding its manufacturing capacities in Vizag and Hyderabad while investing in research and development and backward integration. Cohance aims to expand margins through high-value complex molecules and expects sustained demand from global pharmaceutical clients.
View more
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,757.10 | #1 4,21,587.10 | 40.19 | #1 54,729.00 | 9.71 | #1 10,980 | 2.89 | 71.24 | |
6,511.50 | 1,72,859.90 | 69.56 | 9,712.00 | 18.67 | 2,191 | 35.10 | 49.85 | |
3,831.80 | 1,29,685.50 | 60.73 | 11,539.40 | 6.99 | 1,911 | 30.46 | 70.96 | |
1,532.10 | 1,23,756.00 | 22.77 | 28,409.50 | 7.12 | 5,291 | 3.71 | 48.07 | |
1,246.00 | 1,03,992.90 | #1 18.11 | 33,741.20 | 16.73 | 5,725 | -0.38 | 52.75 | |
944.45 | 95,033.80 | 18.89 | 23,511.00 | 18.55 | 4,615 | 34.60 | 37.46 | |
2,055.30 | 93,876.80 | 21.59 | 22,909.50 | 13.74 | 3,306 | #1 72.75 | 65.62 | |
2,267.10 | 93,576.50 | 52.74 | 12,744.20 | #1 20.90 | 2,007 | -21.05 | 33.43 | |
1,222.50 | 71,003.00 | 20.93 | 32,345.60 | 9.43 | 3,484 | 3.81 | 73.28 | |
5,722.50 | 68,421.10 | 28.40 | 13,458.30 | 3.70 | 2,216 | 10.98 | 64.53 |
Automatic Screeners on ScanX
Growth Rate
Revenue Growth
12.83 %
Net Income Growth
-11.82 %
Cash Flow Change
-19.62 %
ROE
-1.78 %
ROCE
-30.56 %
EBITDA Margin (Avg.)
-17.81 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Total Assets | 783 | 1,173 | 1,475 | 1,830 | 1,966 | 2,254 | 3,032 |
| Fixed Assets | 271 | 357 | 441 | 534 | 663 | 670 | 1,713 |
| Current Assets | 390 | 392 | 565 | 1,128 | 1,011 | 1,263 | 889 |
| Capital Work in Progress | 111 | 102 | 96 | 30 | 165 | 179 | 256 |
| Investments | 7 | 338 | 542 | 598 | 536 | 905 | 337 |
| Other Assets | 394 | 376 | 395 | 667 | 601 | 501 | 726 |
| Total Liabilities | 783 | 1,173 | 1,475 | 1,830 | 1,966 | 2,254 | 3,032 |
| Current Liabilities | 158 | 200 | 220 | 210 | 159 | 107 | 365 |
| Non Current Liabilities | 35 | 128 | 74 | 92 | 72 | 97 | 826 |
| Total Equity | 590 | 845 | 1,181 | 1,527 | 1,735 | 2,051 | 1,841 |
| Reserve & Surplus | 578 | 832 | 1,155 | 1,502 | 1,710 | 2,025 | 1,671 |
| Share Capital | 13 | 13 | 26 | 26 | 26 | 26 | 26 |
Cash Flow
| Cash Flow | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Net Cash Flow | 11 | 1 | -5 | 37 | 20 | -18 | 38 |
| Investing Activities | -66 | -414 | -311 | -136 | -195 | -362 | -253 |
| Operating Activities | 50 | 407 | 383 | 330 | 457 | 359 | 288 |
| Financing Activities | 26 | 7 | -76 | -156 | -242 | -14 | 3 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | May 2025 | Jun 2025 | Sept 2025 |
| Promoter | 60.00 % | 60.00 % | 60.00 % | 60.00 % | 60.00 % | 60.00 % | 60.00 % | 60.00 % | 60.00 % | 60.00 % | 60.00 % | 60.00 % | 50.10 % | 50.10 % | 50.10 % | 50.10 % | 50.10 % | 66.41 % | 66.41 % | 57.49 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 10.01 % | 10.14 % | 9.54 % | 9.80 % | 10.70 % | 10.84 % | 11.05 % | 7.38 % | 7.23 % | 6.51 % |
| DIIs | 4.30 % | 4.47 % | 4.94 % | 5.24 % | 5.91 % | 6.32 % | 10.52 % | 11.35 % | 11.43 % | 9.23 % | 14.14 % | 15.94 % | 17.24 % | 17.42 % | 16.94 % | 16.68 % | 16.60 % | 11.02 % | 11.40 % | 20.82 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % |
| Public / Retail | 20.87 % | 19.86 % | 19.21 % | 18.38 % | 17.07 % | 16.86 % | 14.69 % | 14.01 % | 12.76 % | 12.80 % | 11.76 % | 10.87 % | 10.51 % | 10.08 % | 9.75 % | 9.81 % | 9.68 % | 6.63 % | 6.40 % | 6.42 % |
| Others | 14.84 % | 15.68 % | 15.86 % | 16.38 % | 17.02 % | 16.82 % | 14.78 % | 14.64 % | 15.81 % | 17.97 % | 4.08 % | 3.04 % | 12.59 % | 12.59 % | 12.50 % | 12.56 % | 12.55 % | 8.55 % | 8.55 % | 8.75 % |
| No of Share Holders | 75,207 | 92,534 | 96,532 | 86,447 | 85,725 | 86,088 | 82,577 | 79,412 | 72,885 | 72,167 | 73,715 | 70,052 | 68,932 | 65,777 | 69,337 | 84,210 | 86,325 | 88,658 | 80,910 | 75,284 |
Dividend History
| Annual Cash Flows | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 5 | 2 | 5 | 6 | 0.00 | 0.00 |
| Dividend Yield (%) | 0.00 | 0.00 | 0.00 | 0.00 | 1.01 | 0.32 | 1.06 | 0.89 | 0.00 | 0.00 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 28 Sept 2020 |  Bonus | 1:1 | 25 Sept 2020 | 383.55 | 383.70 |
| 18 Feb 2021 |  Dividend | ₹ 1.00 /share | 17 Feb 2021 | 486.60 | 494.65 |
| 17 Aug 2021 | Dividend | ₹ 1.00 /share | 13 Aug 2021 | 514.80 | 559.70 |
| 16 Feb 2022 | Dividend | ₹ 1.00 /share | 15 Feb 2022 | 558.50 | 522.45 |
| 16 Feb 2022 | Dividend | ₹ 2.00 /share | 15 Feb 2022 | 558.50 | 522.45 |
| 17 May 2022 | Dividend | ₹ 1.00 /share | 13 May 2022 | 580.15 | 507.45 |
| 17 May 2022 | Dividend | ₹ 1.00 /share | 13 May 2022 | 580.15 | 507.45 |
| 12 Sept 2022 | Dividend | ₹ 5.00 /share | 09 Sept 2022 | 492.90 | 477.85 |
| 12 Sept 2022 | Dividend | ₹ 1.00 /share | 09 Sept 2022 | 492.90 | 477.85 |
| 15 Dec 2023 |  Annual General Meeting | NA | 15 Dec 2023 | 572.10 | 673.25 |
| 09 Aug 2024 | Annual General Meeting | NA | 09 Aug 2024 | 848.75 | 990.80 |
| 12 Nov 2024 |  Quarterly Result Announcement | NA | 12 Nov 2024 | 1,197.40 | 1,250.60 |
| 28 Nov 2024 |  Extraordinary General Meeting | NA | 28 Nov 2024 | 1,266.90 | 1,259.05 |
| 12 Feb 2025 | Quarterly Result Announcement | NA | 12 Feb 2025 | 1,148.20 | 1,084.55 |
| 07 May 2025 |  Change Of Name | NA | 07 May 2025 | 1,118.50 | 1,118.50 |
| 28 May 2025 | Quarterly Result Announcement | NA | 28 May 2025 | 1,151.25 | 1,092.20 |
| 13 Aug 2025 | Quarterly Result Announcement | NA | 13 Aug 2025 | 1,002.00 | 949.95 |
| 19 Sept 2025 | Annual General Meeting | NA | 19 Sept 2025 | 980.00 | 912.70 |
| 12 Nov 2025 | Quarterly Result Announcement | NA | 12 Nov 2025 | 869.30 | 691.30 |
Announcements
Announcement under Regulation 30 (LODR)-Newspaper Publication1 day ago
1 day agoAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome3 days ago
3 days agoAnnouncement under Regulation 30 (LODR)-Investor Presentation3 days ago
3 days agoOutcome Of The Meeting3 days ago
3 days agoBoard Meeting Outcome for Outcome Of The Board Meeting3 days ago
3 days agoAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation10 days ago
10 days agoAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation10 days ago
10 days agoAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeNov 01, 2025
Nov 01, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeOct 28, 2025
Oct 28, 2025Announcement under Regulation 30 (LODR)-Change in DirectorateOct 28, 2025
Oct 28, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationOct 28, 2025
Oct 28, 2025General UpdateOct 26, 2025
Oct 26, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Oct 08, 2025
Oct 08, 2025Closure of Trading WindowSep 27, 2025
Sep 27, 2025Board Meeting Intimation for Considering And Approval Of The Unaudited Financial Results (Standalone And Consolidated) Of The Company For The Quarter And Half Year Ending September 30 2025.Sep 27, 2025
Sep 27, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationSep 24, 2025
Sep 24, 2025Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Sep 22, 2025
Sep 22, 2025Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011.Sep 22, 2025
Sep 22, 2025Shareholder Meeting / Postal Ballot-Scrutinizers ReportSep 19, 2025
Sep 19, 2025Shareholder Meeting / Postal Ballot-Outcome of AGMSep 19, 2025
Sep 19, 2025Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Sep 19, 2025
Sep 19, 2025Clarification On Reported News In Electronic MediaSep 18, 2025
Sep 18, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationSep 18, 2025
Sep 18, 2025Disclosure Under SEBI PIT RegulationsSep 18, 2025
Sep 18, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationSep 15, 2025
Sep 15, 2025Completion Of USFDA InspectionSep 11, 2025
Sep 11, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationSep 07, 2025
Sep 07, 2025Letter To Shareholders Regarding Annual ReportAug 28, 2025
Aug 28, 2025General AnnouncementAug 27, 2025
Aug 27, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 27, 2025
Aug 27, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 27, 2025
Aug 27, 2025Announcement under Regulation 30 (LODR)-Credit RatingAug 27, 2025
Aug 27, 2025Business Responsibility and Sustainability Reporting (BRSR)Aug 26, 2025
Aug 26, 2025Reg. 34 (1) Annual Report.Aug 26, 2025
Aug 26, 2025Notice Of AGMAug 26, 2025
Aug 26, 2025Announcement under Regulation 30 (LODR)-Earnings Call TranscriptAug 19, 2025
Aug 19, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 14, 2025
Aug 14, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 14, 2025
Aug 14, 2025Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - Completion Of USFDA InspectionAug 13, 2025
Aug 13, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeAug 13, 2025
Aug 13, 2025Board Meeting Outcome for Outcome Of The Board MeetingAug 13, 2025
Aug 13, 2025Outcome Of The Board MeetingAug 13, 2025
Aug 13, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseAug 12, 2025
Aug 12, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseAug 12, 2025
Aug 12, 2025Giving Of Corporate GuaranteeJul 29, 2025
Jul 29, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJul 28, 2025
Jul 28, 2025Announcement under Regulation 30 (LODR)-Change in ManagementJul 28, 2025
Jul 28, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJul 23, 2025
Jul 23, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJul 22, 2025
Jul 22, 2025Disclosure Under Regulation 30 Of SEBI Listing RegulationsJul 19, 2025
Jul 19, 2025Mutual Fund Holdings
HDFC Balanced Advantage Fund Direct-Growth 
ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct - Growth 
360 ONE Focused Fund Direct-Growth 
Bank of India Small Cap Fund Direct-Growth 
HSBC Multi Cap Fund Direct - Growth 
Union Small Cap Fund Direct-Growth 
DSP Healthcare Fund Direct - Growth 
Bandhan Small Cap Fund Direct-Growth 
WhiteOak Capital Special Opportunities Fund Direct - Growth 
Axis Midcap Direct Plan-Growth 
Tata India Pharma & Healthcare Fund Direct-Growth 
Canara Robeco Small Cap Fund Direct - Growth Technical Indicators
RSI(14)
Oversold 14.20
ATR(14)
Less Volatile 27.44
STOCH(9,6)
Oversold 2.27
STOCH RSI(14)
Oversold 0.00
MACD(12,26)
Bearish -14.80
ADX(14)
Strong Trend 40.45
UO(9)
Bullish 18.96
ROC(12)
Downtrend And Accelerating -28.41
WillR(14)
Oversold -99.50
About Cohance Lifesciences
Suven Pharmaceuticals Limited is an Indian biopharmaceutical company incorporated in 2018. It specializes in contract development and manufacturing operations for the global life sciences industry, focusing on New Chemical Entity-based intermediates, Active Pharmaceutical Ingredients, specialty chemicals, and formulated drugs. The company provides custom synthesis, process R&D, scale-up, and contract manufacturing services. Suven has two wholly owned subsidiaries: Suven Pharma Inc. in the USA and Casper Pharma Private Limited in India. The company operates primarily in India, the United States, Europe, and other global markets, offering various products and services including bulk drugs, intermediates, fine chemicals, and related services. Suven has filed multiple Abbreviated New Drug Applications (ANDAs) and continues to expand its manufacturing capabilities through significant capital expenditure.
Website
Chairperson NameVivek Sharma
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
